PK/Safety Issues

• Fortovase example

  • Increased bioavailability
  • Increased total daily dose
  • Both Safety and Efficacy Issues
    • Required safety database of approx 500 patients followed for 16-24 weeks
    • Required clinical study comparing efficacy of Invirase vs Fortovase

Previous slide

Next slide

Back to first slide

View graphic version